ArticlePharmaceuticals (Basel, Switzerland)2019
New
Article in Pharmaceuticals (Basel, Switzerland), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Radiocobalt-Labeling of a Polypyridylamine Chelate Conjugated to GE11 for EGFR-Targeted Theranostics.Molecules (Basel, Switzerland) · 2025Article
- Controlling the Redox Chemistry of Cobalt Radiopharmaceuticals.Angewandte Chemie (International ed. in English) · 2024Article
- Role of Folate in Liver Diseases.Nutrients · 2024Review
- Preclinical evaluation of [Scientific reports · 2023Article
- PET Imaging of the Neurotensin Targeting Peptide NOTA-NT-20.3 Using Cobalt-55, Copper-64 and Gallium-68.Pharmaceutics · 2022Article
- Non-invasive radionuclide imaging of trace metal trafficking in health and disease: "PET metallomics".RSC chemical biology · 2022Review
- Yields of Photo-Proton Reactions on Nuclei of Nickel and Separation of Cobalt Isotopes from Irradiated Targets.Molecules (Basel, Switzerland) · 2022Article
- Novel PET Imaging of Inflammatory Targets and Cells for the Diagnosis and Monitoring of Giant Cell Arteritis and Polymyalgia Rheumatica.Frontiers in medicine · 2022Review
- Active Targeted Nanoformulations via Folate Receptors: State of the Art and Future Perspectives.Pharmaceutics · 2021Review
- Production, Purification, and Applications of a Potential Theranostic Pair: Cobalt-55 and Cobalt-58m.Diagnostics (Basel, Switzerland) · 2021Review
- Pharmacokinetic Properties ofMolecules (Basel, Switzerland) · 2020Article
- Development of Folate Receptor-Targeted PET Radiopharmaceuticals for Tumor Imaging-A Bench-to-Bedside Journey.Cancers · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Overexpression of folate receptors (FRs) on different tumor types (e.g., ovarian, lung) make FRs attractive in vivo targets for directed diagnostic/therapeutic agents. Currently, no diagnostic agent suitable for positron emission tomography (PET) has been adopted for clinical FR imaging. In this work, two
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.